TY - JOUR
T1 - Direct Activation of Cytosolic Ca2+ Signaling and Enzyme Secretion by Cholecystokinin in Human Pancreatic Acinar Cells
AU - Murphy, John A.
AU - Criddle, David N.
AU - Sherwood, Mark
AU - Chvanov, Michael
AU - Mukherjee, Rajarshi
AU - McLaughlin, Euan
AU - Booth, David
AU - Gerasimenko, Julia V.
AU - Raraty, Michael G.T.
AU - Ghaneh, Paula
AU - Neoptolemos, John P.
AU - Gerasimenko, Oleg V.
AU - Tepikin, Alexei V.
AU - Green, Gary M.
AU - Reeve, Joseph R.
AU - Petersen, Ole H.
AU - Sutton, Robert
PY - 2008/8
Y1 - 2008/8
N2 - Background & Aims: Cholecystokinin (CCK) has been thought to act only indirectly on human pancreatic acinar cells via vagal nerve stimulation, rather than by direct CCK receptor activation as on rodent pancreatic acinar cells. We tested whether CCK (CCK-8 and human CCK-58) can act directly on human pancreatic acinar cells. Methods: Human acinar cells were freshly isolated from pancreatic transection line samples, loaded with Fluo4-AM or quinacrine, and examined for Ca2+, metabolic and secretory responses to CCK-8, human CCK-58, or acetylcholine with confocal microscopy. Results: CCK-8 and human CCK-58 at physiologic concentrations (1-20 pmol/L) elicited rapid, robust, oscillatory increases of the cytosolic Ca2+ ion concentration, showing apical to basal progression, in acinar cells from 14 patients with unobstructed pancreata. The cytosolic Ca2+ ion concentration increases were followed by increases in mitochondrial adenosine triphosphate production and secretion. CCK-elicited Ca2+ signals and exocytosis were not inhibited by atropine (1 μmol/L) or tetrodotoxin (100 nmol/L), showing that CCK was unlikely to have acted via neurotransmitter release. CCK-elicited Ca2+ signals were inhibited reversibly by caffeine (5-20 mmol/L), indicating involvement of intracellular inositol trisphosphate receptor Ca2+ release channels. Acetylcholine (50 nmol/L) elicited similar Ca2+ signals. Conclusions: CCK at physiologic concentrations in the presence of atropine and tetrodotoxin elicits cytosolic Ca2+ signaling, activates mitochondrial function, and stimulates enzyme secretion in isolated human pancreatic acinar cells. We conclude that CCK acts directly on acinar cells in the human pancreas.
AB - Background & Aims: Cholecystokinin (CCK) has been thought to act only indirectly on human pancreatic acinar cells via vagal nerve stimulation, rather than by direct CCK receptor activation as on rodent pancreatic acinar cells. We tested whether CCK (CCK-8 and human CCK-58) can act directly on human pancreatic acinar cells. Methods: Human acinar cells were freshly isolated from pancreatic transection line samples, loaded with Fluo4-AM or quinacrine, and examined for Ca2+, metabolic and secretory responses to CCK-8, human CCK-58, or acetylcholine with confocal microscopy. Results: CCK-8 and human CCK-58 at physiologic concentrations (1-20 pmol/L) elicited rapid, robust, oscillatory increases of the cytosolic Ca2+ ion concentration, showing apical to basal progression, in acinar cells from 14 patients with unobstructed pancreata. The cytosolic Ca2+ ion concentration increases were followed by increases in mitochondrial adenosine triphosphate production and secretion. CCK-elicited Ca2+ signals and exocytosis were not inhibited by atropine (1 μmol/L) or tetrodotoxin (100 nmol/L), showing that CCK was unlikely to have acted via neurotransmitter release. CCK-elicited Ca2+ signals were inhibited reversibly by caffeine (5-20 mmol/L), indicating involvement of intracellular inositol trisphosphate receptor Ca2+ release channels. Acetylcholine (50 nmol/L) elicited similar Ca2+ signals. Conclusions: CCK at physiologic concentrations in the presence of atropine and tetrodotoxin elicits cytosolic Ca2+ signaling, activates mitochondrial function, and stimulates enzyme secretion in isolated human pancreatic acinar cells. We conclude that CCK acts directly on acinar cells in the human pancreas.
UR - http://www.scopus.com/inward/record.url?scp=48549100809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48549100809&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2008.05.026
DO - 10.1053/j.gastro.2008.05.026
M3 - Article
C2 - 18555802
AN - SCOPUS:48549100809
VL - 135
SP - 632
EP - 641
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 2
ER -